10.26442/2075-1753_2016.8.101-104

Vollständiger Abstract

Worum geht es in dieser Arbeit?

<h4>Aim</h4>To evaluate the efficacy, safety and impact on gastrointestinal symptoms of Helicobacter pylori eradication therapy with a ready-to-use set of tablets and capsules [omeprazole 20 mg × 2, clarithromycin 500 mg × 2, amoxicillin 500 mg × 4] (Pylobact ® AM) in duodenal ulcer patients within the framework of an observational program.<h4>Materials and methods</h4>912 <i>H. pylori</i>-positive patients were included (404 men and 508 women, average age - 43.8 years (43.82±11.39; 18-64 years). Symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire; patients assessed treatment satisfaction, and physicians assessed treatment efficacy and tolerability using a five-point Likert scale. The efficacy of<i> H. pylori </i>eradication was assessed using the results of the 13 C-urea breath test,<i> H. pylori </i>antigen stool test, or a rapid urea test with biopsies of the gastric body and antrum obtained during upper endoscopy. A total of 870 patients completed the observational program: 538 patients in the standard triple therapy group (PAM group) and 332 patients in the group enhanced with a bismuth preparation, rebamipide, and/or a probiotic (PAMplus group). A subgroup of patients received triple therapy with bismuth and the synbiotic complex of Floriose with probiotic strains <i>Lactobacillus acidophilus La-14, Lactobacillus rhamnosus Lr-32, Bifidobacterium lactis Bl-04,</i> inulin and B vitamins.<h4>Results</h4><i> H. pylori </i>eradication rates in the PAM, PAMplus, and PAM+Bi+F (ITT) groups were 90.6, 97.03, and 96.82%, respectively. Treatment significantly reduced GSRS abdominal pain scores. Physicians rated the treatment efficacy and tolerability as "very good" or "good" at the end of the program in 93.3% of patients. Patients rated 93.68% as completely or mostly satisfied with the treatment.<h4>Conclusion</h4>The effectiveness of<i> H. pylori </i>eradication with a ready-to-use set of capsules and tablets for standard triple therapy is ensured by high patient compliance. The combination of standard triple therapy with bismuth, probiotics, and/or rebamipide increases treatment efficacy.

Abstract: PubMed · Datensatz